Cayman Biomedical Research Insititute (CABRI) has announced its 2020 awardees for novel treatments for rare disease funding. Steph Barrett, VP of R&D and Director on the board of CARBI, said “We are excited to support these scientists actively researching treatments for often poorly funded diseases”.
2020 Principal Investigators
$75,000 - Dr. Sven-Erik Dahlén, Karolinska Institute, to target prostaglandin D2 biosynthesis in the treatment of mast cell activation disorders (e.g., mastocytosis, asthma, allergic reactions)
$60,000 - Dr. Michael Holinstat, University of Michigan, to assess the 12-lipoxygenase inhibitor development lead ML355 as a heparin alternative for regulating platelet function in an animal model of heparin-induced thrombocytopenia and thrombosis
$50,000 - Dr. Amanda Huber, University of Michigan, to study how mesenchymal stem cell-specific KDM6B regulates heterotopic ossification in fibrodysplasia ossificans progressive (FOP)
$15,000 - Dr. David Aronoff, Vanderbilt University Medical Center, to measure Clostridium septicum alpha toxin by enzyme-linked immunosorbent assay in an infection model
2020 Undergraduate Grants
$5,000 - Abdelkarim Khalid, St. Olaf College, for the physiological investigation of magnetoreception in the avian retina
$4,000 - Madeline Maslyar, Boston Children’s Hospital, for the identification of small molecules that induce immunological tolerance following transplantation
$4,000 - Meghana Sankaran, University of Miami, for the optimization of dual drug delivery for pediatric brain tumors
$3,500 - Dani Maydan, University of Michigan, for promoting differentiation as a novel strategy for the treatment of diffuse intrinsic pontine glioma
$3,500 - Ellen Lauinger, University of Michigan, to examine the effect of impaired cardiac energetics on mTORC1 in heart failure